Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02845323Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2017
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of urelumab in urothelial carcinoma (UC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started May 2017; status: active, not recruiting.
02
Drugs
urelumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02845323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02845323.